tetano
Editor, Senior Moderator
JCI Insight
. 2024 Oct 22;9(20):e183913.
doi: 10.1172/jci.insight.183913. Antibody levels versus vaccination status in the outcome of older adults with COVID-19
Sylvia Mink[SUP] 1 2 [/SUP], Christoph H Saely[SUP] 2 3 [/SUP], Andreas Leiherer[SUP] 1 3 [/SUP], Patrick Reimann[SUP] 2 4 [/SUP], Matthias Frick[SUP] 4 [/SUP], Janne Cadamuro[SUP] 5 [/SUP], Wolfgang Hitzl[SUP] 6 [/SUP], Heinz Drexel[SUP] 2 3 7 [/SUP], Peter Fraunberger[SUP] 1 2 [/SUP]
Affiliations
BACKGROUNDDespite the currently prevailing, milder Omicron variant of COVID-19, older adults remain at elevated risk of hospital admission, critical illness, and death. Loss of efficacy of the immune system, including reduced strength, quality, and durability of antibody responses, may render generalized recommendations on booster vaccinations inadequate. There is a lack of data on the efficacy of antibody levels in older adults and on the utility of vaccination status versus antibody levels as a correlate of protection. It is further unclear whether antibody levels may be used to guide the timing of booster vaccinations in older adults.METHODSWe conducted a prospective multicenter cohort study comprising hospitalized patients with COVID-19. Anti-SARS-CoV-2 spike antibodies were measured on hospital admission. The primary endpoint was in-hospital mortality. Patients were stratified by age, antibody levels, and vaccination status. Multiple logistic regression and Cox regression analyses were conducted.RESULTSIn total, 785 older patients (≥60 years of age [a]) and 367 controls (<60a) were included. After adjusting for confounders, risk of mortality, ICU admission, endotracheal intubation, and oxygen administration was 4.9, 2.6, 6.5, and 2.3 times higher, respectively, if antibody levels were < 1,200 BAU/mL (aOR, 4.92 [95%CI, 2.59-9.34], P < 0.0001; aOR, 2.64 [95%CI, 1.52-4.62], P = 0.0006; aOR, 6.50 [95%CI, 1.48-28.47], P = 0.013; aOR, 2.34 [95%CI, 1.60-3.343], P < 0.0001). Older adults infected with the Omicron variant were approximately 6 times more likely to die if antibody levels were < 1,200 BAU/mL (aOR, 6.3 [95% CI, 2.43-16.40], P = 0.0002).CONCLUSIONAntibody levels were a stronger predictor of in-hospital mortality than vaccination status. Monitoring antibody levels may constitute a better and more direct approach for safeguarding older adults from adverse COVID-19 outcomes.
Keywords: Clinical practice; Infectious disease; Vaccines.
. 2024 Oct 22;9(20):e183913.
doi: 10.1172/jci.insight.183913. Antibody levels versus vaccination status in the outcome of older adults with COVID-19
Sylvia Mink[SUP] 1 2 [/SUP], Christoph H Saely[SUP] 2 3 [/SUP], Andreas Leiherer[SUP] 1 3 [/SUP], Patrick Reimann[SUP] 2 4 [/SUP], Matthias Frick[SUP] 4 [/SUP], Janne Cadamuro[SUP] 5 [/SUP], Wolfgang Hitzl[SUP] 6 [/SUP], Heinz Drexel[SUP] 2 3 7 [/SUP], Peter Fraunberger[SUP] 1 2 [/SUP]
Affiliations
- PMID: 39435658
- DOI: 10.1172/jci.insight.183913
BACKGROUNDDespite the currently prevailing, milder Omicron variant of COVID-19, older adults remain at elevated risk of hospital admission, critical illness, and death. Loss of efficacy of the immune system, including reduced strength, quality, and durability of antibody responses, may render generalized recommendations on booster vaccinations inadequate. There is a lack of data on the efficacy of antibody levels in older adults and on the utility of vaccination status versus antibody levels as a correlate of protection. It is further unclear whether antibody levels may be used to guide the timing of booster vaccinations in older adults.METHODSWe conducted a prospective multicenter cohort study comprising hospitalized patients with COVID-19. Anti-SARS-CoV-2 spike antibodies were measured on hospital admission. The primary endpoint was in-hospital mortality. Patients were stratified by age, antibody levels, and vaccination status. Multiple logistic regression and Cox regression analyses were conducted.RESULTSIn total, 785 older patients (≥60 years of age [a]) and 367 controls (<60a) were included. After adjusting for confounders, risk of mortality, ICU admission, endotracheal intubation, and oxygen administration was 4.9, 2.6, 6.5, and 2.3 times higher, respectively, if antibody levels were < 1,200 BAU/mL (aOR, 4.92 [95%CI, 2.59-9.34], P < 0.0001; aOR, 2.64 [95%CI, 1.52-4.62], P = 0.0006; aOR, 6.50 [95%CI, 1.48-28.47], P = 0.013; aOR, 2.34 [95%CI, 1.60-3.343], P < 0.0001). Older adults infected with the Omicron variant were approximately 6 times more likely to die if antibody levels were < 1,200 BAU/mL (aOR, 6.3 [95% CI, 2.43-16.40], P = 0.0002).CONCLUSIONAntibody levels were a stronger predictor of in-hospital mortality than vaccination status. Monitoring antibody levels may constitute a better and more direct approach for safeguarding older adults from adverse COVID-19 outcomes.
Keywords: Clinical practice; Infectious disease; Vaccines.